US Edition
B.C. Limits Sales of Two More Diabetes Drugs Amid Off-Label Use for Weight Loss
BRITISH COLUMBIA, CANADA, JUL 17 – British Columbia restricts Mounjaro and Trulicity sales to prevent off-label weight loss use and maintain supply for diabetes patients, following similar 2023 semaglutide limits.
- British Columbia's Health Ministry announced it will limit sales of tirzepatide and dulaglutide to curb off-label weight loss use and preserve supplies for diabetics.
- This action builds on a 2023 policy that limited semaglutide sales and addresses supply issues caused by off-label weight loss use impacting multiple nations such as the US.
- Pharmacies cannot sell these drugs to non-citizens or non-permanent residents unless the person picks up the medication in person, but valid prescriptions remain necessary for all buyers.
- Health Minister Josie Osborne noted that the demand for these medications as weight-loss treatments is causing supply issues in multiple nations, including the United States, while the College of Pharmacists is responsible for enforcing regulations among its members.
- The province continues efforts to guarantee diabetes patients reliable medication access, noting that non-residents with valid Canadian prescriptions may still purchase drugs by appearing in person.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
Prince George Citizen+4 Reposted by 4 other sources
B.C. limits sales of two more diabetes drugs amid off-label use for weight loss
VICTORIA — British Columbia's Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.
·Prince George, Canada
Read Full Article
B.C. limits sales of two more diabetes drugs amid off-label use for weight loss – Energeticcity.ca
VICTORIA — British Columbia’s Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic. The limits on sales of Type 2 diabetes drugs tirzepatide and dulaglutide come after a 2023 regulation limited sales of semaglutide, which is sold under the band name Ozempic. The rules mean B.C. pharmacists will not be able to sell the drugs to people who are n…
Coverage Details
Total News Sources11
Leaning Left8Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
